Lymphogenesis is a complex multi-step process in which dysregulation of lymphocyte signaling pathways, transcriptional regulation, and apoptosis machinery leads to transformation. In the initial period of this grant, we built upon observations from a naturally-occurring bovine pseudo- leukemia syndrome and from studies of human tumor specimens to develop a model system to investigate the role of the regulatory serine studies of human tumor specimens to develop a model system to investigate the role of the regulatory serine-threonine kinase CK2 (formerly termed casein kinase II) in lymphomagenesis. These experiments have shown that dysregulated expression of CK2alpha does in fact predispose to lymphoma, and that CK2alpha over-expression synergizes with deficiency of the tumor suppressor gene p53 to accelerate lymphomagenesis. Further experiments have demonstrated that CK2alpha lymphomas constitutively up-regulate a panel of lymphocyte transcription factor families including AP-1, NFkappaB, CREB, NFAT, and TCF/LEF. Normally, these factors appear to be involved in physiological activation responses of lymphocytes rather than in malignant growth control. In the proposed experiments, the role of CK2alpha in the direct or indirect regulation of these transcriptional factors to lymphocyte transformation in vitro and in vivo. To answer the question of how essential CK2alpha is to normal lymphocyte growth using a genetic approach, we will develop a CDK2alpha """"""""knockout"""""""" mouse model. We will also assess the impact of the other CK2 subunits, CK2alpha' and CK2beta, upon lymphocyte growth and development in a combination of transgenic and knockout experiments. These studies will fully elucidate the role of the CK2 subunits in lymphocyte development and transformation, and will also provide important new insights into the pathogenic contribution that constitutively expressed transcriptional activators may make to lymphomagenesis. In addition to expanding our understanding of growth control pathways in lymphocytes, it is hoped that these studies will contribute to the development of new anti-tumor therapies in the future, directed against proven kinase CDK2 itself or collaborating oncogenic transcription factors.
| Imbrie, Gregory A; Wu, Hao; Seldin, David C et al. (2012) Asymmetric Localization of CK2? During Xenopus Oogenesis. Hum Genet Embryol Suppl 4:11328 |
| Dominguez, Isabel; Degano, Irene R; Chea, Kathleen et al. (2011) CK2? is essential for embryonic morphogenesis. Mol Cell Biochem 356:209-16 |
| Landesman-Bollag, Esther; Belkina, Anna; Hovey, Beth et al. (2011) Developmental and growth defects in mice with combined deficiency of CK2 catalytic genes. Mol Cell Biochem 356:227-31 |
| Currier, Nicolas; Chea, Kathleen; Hlavacova, Mirka et al. (2010) Dynamic expression of a LEF-EGFP Wnt reporter in mouse development and cancer. Genesis 48:183-94 |
| Wu, Hao; Symes, Karen; Seldin, David C et al. (2009) Threonine 393 of beta-catenin regulates interaction with Axin. J Cell Biochem 108:52-63 |
| Dominguez, I; Sonenshein, G E; Seldin, D C (2009) Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer. Cell Mol Life Sci 66:1850-7 |
| Chitalia, Vipul C; Foy, Rebecca L; Bachschmid, Markus M et al. (2008) Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol 10:1208-16 |
| Seldin, David C; Lou, David Y; Toselli, Paul et al. (2008) Gene targeting of CK2 catalytic subunits. Mol Cell Biochem 316:141-7 |
| Lou, David Y; Dominguez, Isabel; Toselli, Paul et al. (2008) The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol 28:131-9 |
| Belguise, Karine; Guo, Shangqin; Yang, Shi et al. (2007) Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res 67:11742-50 |
Showing the most recent 10 out of 22 publications
